Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Hightide Therapeutics Inc ( (HK:2511) ) is now available.
HighTide Therapeutics announced positive results from its Phase III HARMONY trial, where its drug HTD1801 showed superior improvements in cardiometabolic markers for patients with type 2 diabetes mellitus compared to dapagliflozin. The trial’s success underscores HTD1801’s potential as a foundational therapy in CKM disease management, and the company plans to submit a New Drug Application later this year.
More about Hightide Therapeutics Inc
HighTide Therapeutics, Inc. is a biopharmaceutical company focused on developing multifunctional, multi-targeted therapies for chronic metabolic diseases. The company emphasizes addressing the residual risks of cardiovascular-kidney-metabolic (CKM) syndrome and has built a globally integrated pipeline of proprietary assets. Its lead asset, HTD1801, has received Fast Track and Orphan Drug designations from the US FDA.
Average Trading Volume: 1,096,778
Technical Sentiment Signal: Hold
Current Market Cap: HK$1.42B
Learn more about 2511 stock on TipRanks’ Stock Analysis page.